We are live on ! Find out more
LSBPW

LakeShore Biopharma Warrants
LSBPW

Delisted

LSBPW was delisted on the 19th of September, 2025.

Back to rankings

30 hedge funds and large institutions have $356K invested in LakeShore Biopharma Warrants in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

17% more capital invested

Capital invested by funds: $304K → $356K (+$51.7K)

6.36% more ownership

Funds ownership: 0% → 6.36% (+6.4%)

3% less funds holding

Funds holding: 31 → 30 (-1)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
30
Holders Change
-1
Holders Change %
-3.23%
% of All Funds
0.48%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
–
Increased
1
Reduced
4
Closed
1
Calls
$42K
Puts
–
Net Calls
+$42K
Net Calls Change
-$14K

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$5

Top Sellers

Rank Fund Capital Flow
1
RCM
Radcliffe Capital Management
Pennsylvania
-$2.21K
2
AC
Athos Capital
Hong Kong
-$1.1K
3
AA
AQR Arbitrage
Connecticut
-$781
4
LCM
Landscape Capital Management
New Jersey
-$470
5
UBS Group
UBS Group
Switzerland
-$234
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Athos Capital
Hong Kong
$103K -$1.1K -21,018 -14%
LP
2
LMR Partners
United Kingdom
$43.4K – – –
VAM
3
Valliance Asset Management
Hong Kong
$30.9K – – –
HCM
4
Highbridge Capital Management
New York
$22.2K – – –
SLM
5
Snow Lake Management
California
$20.6K – – –
Jane Street
6
Jane Street
New York
$20.5K – – –
BP
7
BFAM Partners
Hong Kong
$19.3K – – –
FC
8
Finepoint Capital
Massachusetts
$17.1K – – –
ICM
9
Ionic Capital Management
New York
$11.3K – – –
BCL
10
Bracebridge Capital LLC
Massachusetts
$9.57K – – –
CAC
11
Cowen and Company
New York
$8.24K +$5 +100 +0.1%
WA
12
Whitebox Advisors
Minnesota
$5.15K – – –
Calamos Advisors
13
Calamos Advisors
Illinois
$5.11K – – –
QGA
14
Q Global Advisors
Texas
$5K – – –
Walleye Capital
15
Walleye Capital
New York
$4.12K – – –
ETH
16
Exos TFP Holdings
New York
$4.08K – – –
SCM
17
Saba Capital Management
New York
$4.01K – – –
SCM
18
Shaolin Capital Management
Florida
$4K – – –
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$3.5K – – –
CF
20
Cantor Fitzgerald
New York
$3.17K – – –
RCM
21
Radcliffe Capital Management
Pennsylvania
$2.42K -$2.21K -42,264 -42%
CS
22
Clear Street
New York
$1.95K – – –
SVI
23
Strategic Vision Investment
Hong Kong
$1.6K – – –
EC
24
Elequin Capital
New York
$1.54K – – –
AA
25
AQR Arbitrage
Connecticut
$1.49K -$781 -14,967 -26%
1
2

LSBPW Hedge Fund Activity: Q3 2023 in Review

30 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q3 2023, worth a combined $356K — up 17% from $304K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of LSBPW and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.

The largest buyer was Cowen and Company, adding an estimated $5. The largest seller was Radcliffe Capital Management, cutting an estimated $2.21K.

  • 30 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q3 2023, down from 31 in Q2 2023.
  • Funds reported $356K of LakeShore Biopharma Warrants stock for Q3 2023, up 17% quarter-over-quarter.
  • 0 funds opened new LakeShore Biopharma Warrants positions in Q3 2023 and 1 closed out, a net change of -1 holder.
  • The largest LakeShore Biopharma Warrants buyer in Q3 2023 was Cowen and Company, an estimated $5 added.
  • The largest LakeShore Biopharma Warrants seller in Q3 2023 was Radcliffe Capital Management, an estimated $2.21K sold.

Based on aggregated 13F filings for Q3 2023.